This led to the creation of a refined signature that could more accurately predict ATC’s immune responsiveness to anti-PD1 therapy, which was further corroborated using thyroid cancer cohorts and 9 melanoma cohorts from the clinical trial. The gene discussed is PDCD1; the disease is thyroid cancer.